Navigation Links
Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Date:10/25/2007

Primary Analysis of Pivotal Trial to Be Available No Later Than July 2008

SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced that an independent Data Monitoring Board (DMB) was recently convened to assess time to tumor progression (TTP) for patients in the control group of the Company's pivotal Phase 3 clinical trial of FavId(R). The DMB assessment, which was conducted in accordance with the clinical protocol under Favrille's Special Protocol Assessment (SPA) with the Food & Drug Administration (FDA), indicated that the control group behavior is consistent with data reported in the published literature. Based in part on the guidance provided by the DMB, Favrille has determined April 2008 to be the appropriate time for data cutoff of the Phase 3 trial. The Company anticipates that the analysis of the data will be completed and made available no later than July 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)

The Phase 3 trial is a randomized, double-blind, placebo controlled trial of FavId following Rituxan(R) treatment in patients with follicular B-cell non-Hodgkin's lymphoma (NHL). A total of 349 patients were randomly assigned to receive either FavId plus Leukine(R) (sargramostim, GM-CSF) or placebo plus Leukine following a course of Rituxan treatment. The primary endpoint of this trial is TTP.

"As we previously communicated, the rate of progression in our pivotal Phase 3 trial has slowed during the past 12 months," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "We believe this is a positive development, and it has shifted our focus for data cutoff and analysis to trial follow-up time as allowed in the protocol rather than the number of patient progressi
'/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
5. XTL Provides Update on Phase I Clinical Trial of XTL-2125
6. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
7. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
8. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
9. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
10. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
11. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... NEW YORK , July 30, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p0356852/mHealth-and-Home-Monitoring-–-6th-Edition.html Executive ... services are delivered, leading to better outcomes, decreased ... The market for mHealth solutions is still in ...
(Date:7/30/2014)... 30, 2014  InnoPharma, Inc. today announced the first ... equivalent of Zyprexa® injection), in Canada.  Olanzapine is indicated ... in patients with schizophrenia or bipolar I mania. ... InnoPharma has entered into an agreement with Sandoz Canada ... make, use, sell, market and distribute Olanzapine Injection in ...
(Date:7/30/2014)... , July 30, 2014 Stryker brand ambassadors ... week at the 3M Championship Champions Tour event near ... in Blaine . Stryker is the official joint ... Starting Friday, August 1 st through Sunday, August ... Mobility Zone; an on-site joint health destination located in the Pioneer ...
Breaking Medicine Technology:mHealth and Home Monitoring - 6th Edition 2mHealth and Home Monitoring - 6th Edition 3mHealth and Home Monitoring - 6th Edition 4mHealth and Home Monitoring - 6th Edition 5mHealth and Home Monitoring - 6th Edition 6mHealth and Home Monitoring - 6th Edition 7mHealth and Home Monitoring - 6th Edition 8mHealth and Home Monitoring - 6th Edition 9mHealth and Home Monitoring - 6th Edition 10mHealth and Home Monitoring - 6th Edition 11InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5
(Date:7/30/2014)... Dennis Thompson HealthDay Reporter ... people with depression are more likely to develop dementia, but ... the relationship between the two. Specifically, they haven,t been ... works -- does depression help bring on dementia, or does ... published online July 30 in the journal Neurology ...
(Date:7/30/2014)... Ticket Down is a reputable source for ... MI on Saturday, August 2nd. Two of the most ... competing on American soil on Aug. 2 when Manchester United and ... The home of the University of Michigan is also known as ... all of American sports and has also hosted numerous other monumental ...
(Date:7/30/2014)... VA (PRWEB) July 30, 2014 ... be featured in an upcoming episode of Innovations ... via Discovery Channel. Dates and show times TBA. ... on Good Neighbor Community Services’ vision to redefine ... providing individualized and dynamic services. Through passion, innovation, ...
(Date:7/30/2014)... HealthDay Reporter WEDNESDAY, July ... their preschooler shed excess pounds may want to team up ... joined them in a supervised behavioral modification program gained less ... child-only program (an average difference of about four pounds over ... pounds over two years, according to the study. "In ...
(Date:7/30/2014)... Volunteers from the Church of Scientology of Denmark ... with massive distribution of Truth About Drugs ... on Strøget, the famous Copenhagen walking street. Popular ... its ambiance, some quarter of a million people stroll ... , These activities are part of a coordinating effort ...
Breaking Medicine News(10 mins):Health News:Scientists Shed Light on Link Between Depression, Dementia 2Health News:Scientists Shed Light on Link Between Depression, Dementia 3Health News:Manchester United vs. Real Madrid Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for Real Madrid vs. ManU Guinness International Champions Cup Match 2Health News:Manchester United vs. Real Madrid Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for Real Madrid vs. ManU Guinness International Champions Cup Match 3Health News:Manchester United vs. Real Madrid Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for Real Madrid vs. ManU Guinness International Champions Cup Match 4Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4
... 90% adhered to fluid restriction, weigh-ins when aided by ... -- Intensive support from a heart failure nurse and ... patients will comply with crucial non-medical interventions, such as ... study by Dutch researchers. , "We examined the ...
... meds reduced risk by as much as 60%, researchers ... over-the-counter pain medicines called non-steroidal anti-inflammatory drugs (NSAIDs) may ... study by researchers at the UCLA School of Public ... men and women (half with Parkinson,s disease) who were ...
... liver transplantation who also suffer from other medical ... These comorbid problems, which include coronary disease, diabetes, ... and renal insufficiency, have been incorporated into a ... survival. These findings are published in the November ...
... ANGELES, Nov. 5 Tri-Isthmus Group, Inc.,("TIGroup"), (OTC ... the healthcare industry, announced the acquisition of a ... in Oklahoma City,RHA owns and operates three critical ... TIGroup,s Chairman and CEO, David Hirschhorn said, ...
... Video Captures Support for Contributions to the Environment and ... ... a new online video and podcast,released today, 14 globally recognized and ... food,crops over the last decade -- including their proven safety, benefits ...
... Rehabilitation on Heart Disease Patients with,Depression To ... Scientific,Sessions in Orlando, FLUSHING, N.Y., Nov. 5 ... New York Hospital Queens Heart and Vascular,Center demonstrates ... positive impact on depression in patients with coronary ...
Cached Medicine News:Health News:Nurse-Led Intervention Boosts Cardiac Rehab: Study 2Health News:NSAIDs Protect Against Parkinson's Disease 2Health News:Predicting survival after liver transplantation 2Health News:TIGroup Acquires Controlling Interest in Healthcare Services Provider 2Health News:TIGroup Acquires Controlling Interest in Healthcare Services Provider 3Health News:Fourteen Global Experts Comment on the Safety and Use of Genetically Modified Food Crops 2Health News:Fourteen Global Experts Comment on the Safety and Use of Genetically Modified Food Crops 3Health News:Fourteen Global Experts Comment on the Safety and Use of Genetically Modified Food Crops 4Health News:New York Hospital Queens Cardiac Rehabilitation Team Presents Study at World's Leading Heart Disease Conference 2Health News:New York Hospital Queens Cardiac Rehabilitation Team Presents Study at World's Leading Heart Disease Conference 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: